# Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

> **NCT01028027** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 357 (actual)

## Conditions studied

- Conjunctivitis
- Keratitis
- Blepharitis

## Interventions

- **DRUG:** Loteprednol and tobramycin
- **DRUG:** Tobramycin and dexamethasone

## Key facts

- **NCT ID:** NCT01028027
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-03
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2012-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028027, "Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01028027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*